SCYNEXIS: SCY-770 well tolerated in Phase 1 for ADPKD

SCYNEXIS reported completed Phase 1 results for SCY-770, an oral AMPK activator in development for ADPKD. Results showed the drug was well tolerated with a favorable safety profile in healthy adults.